CV Sciences Inc
CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements, hemp-based cannabidiol (CBD), and plant based food products in North America. It offers its products under the PlusCBD, PlusHLTH, Cultured Foods, and Lunar Fox brand names in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, select distributor… Read more
CV Sciences Inc (CVSI) - Total Assets
Latest total assets as of September 2025: $7.00 Million USD
Based on the latest financial reports, CV Sciences Inc (CVSI) holds total assets worth $7.00 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CV Sciences Inc - Total Assets Trend (2012–2024)
This chart illustrates how CV Sciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
CV Sciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
CV Sciences Inc's total assets of $7.00 Million consist of 78.8% current assets and 21.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.7% |
| Accounts Receivable | $522.00K | 6.6% |
| Inventory | $4.90 Million | 61.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $93.00K | 1.2% |
| Goodwill | $971.00K | 12.3% |
Asset Composition Trend (2012–2024)
This chart illustrates how CV Sciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CV Sciences Inc's current assets represent 78.8% of total assets in 2024, an increase from 0.0% in 2012.
- Cash Position: Cash and equivalents constituted 5.7% of total assets in 2024, down from 100.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 61.8% of total assets.
CV Sciences Inc Competitors by Total Assets
Key competitors of CV Sciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
CV Sciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - CV Sciences Inc generates 1.98x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - CV Sciences Inc is currently not profitable relative to its asset base.
CV Sciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.06 | 1.10 | 1.18 |
| Quick Ratio | 0.21 | 0.28 | 0.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $311.00K | $ 605.00K | $ 2.53 Million |
CV Sciences Inc - Advanced Valuation Insights
This section examines the relationship between CV Sciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.09 |
| Latest Market Cap to Assets Ratio | 0.64 |
| Asset Growth Rate (YoY) | -13.8% |
| Total Assets | $7.93 Million |
| Market Capitalization | $5.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values CV Sciences Inc's assets below their book value (0.64 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: CV Sciences Inc's assets decreased by 13.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for CV Sciences Inc (2012–2024)
The table below shows the annual total assets of CV Sciences Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $7.93 Million | -13.84% |
| 2023-12-31 | $9.20 Million | -27.76% |
| 2022-12-31 | $12.74 Million | -29.50% |
| 2021-12-31 | $18.07 Million | -41.01% |
| 2020-12-31 | $30.62 Million | -41.87% |
| 2019-12-31 | $52.69 Million | +42.78% |
| 2018-12-31 | $36.90 Million | +62.49% |
| 2017-12-31 | $22.71 Million | +22.15% |
| 2016-12-31 | $18.59 Million | -31.88% |
| 2015-12-31 | $27.30 Million | +25.55% |
| 2014-12-31 | $21.74 Million | +52.75% |
| 2013-12-31 | $14.23 Million | +1423100.00% |
| 2012-12-31 | $1.00K | -- |